Enlivex Therapeutics Statistics

Total Valuation

Enlivex Therapeutics has a market cap or net worth of ILS 84.05 million. The enterprise value is -9.84 million.

Market Cap	84.05M
Enterprise Value	-9.84M

Important Dates

The last earnings date was Friday, November 8, 2024.

Earnings Date	Nov 8, 2024
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+2.08%
Shares Change (QoQ)	+4.37%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	15.55M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	0.12
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	0.15

Financial Position

The company has a current ratio of 10.06, with a Debt / Equity ratio of 0.03.

Current Ratio	10.06
Quick Ratio	9.57
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.05
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -61.17% and return on invested capital (ROIC) is -29.86%.

Return on Equity (ROE)	-61.17%
Return on Assets (ROA)	-27.46%
Return on Capital (ROIC)	-29.86%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -34.04% in the last 52 weeks. The beta is 1.04, so Enlivex Therapeutics's price volatility has been similar to the market average.

Beta (5Y)	1.04
52-Week Price Change	-34.04%
50-Day Moving Average	535.12
200-Day Moving Average	736.16
Relative Strength Index (RSI)	18.02
Average Volume (20 Days)	48,311

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.25

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-70.24M
Pretax Income	-83.94M
Net Income	-83.94M
EBITDA	-67.37M
EBIT	-70.24M
Earnings Per Share (EPS)	-4.45

Full Income Statement

Balance Sheet

The company has 97.67 million in cash and 3.14 million in debt, giving a net cash position of 94.53 million.

Cash & Cash Equivalents	97.67M
Total Debt	3.14M
Net Cash	94.53M
Net Cash Per Share	n/a
Equity (Book Value)	107.54M
Book Value Per Share	5.15
Working Capital	96.87M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -64.09 million and capital expenditures -357,685, giving a free cash flow of -64.45 million.

Operating Cash Flow	-64.09M
Capital Expenditures	-357,685
Free Cash Flow	-64.45M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Enlivex Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.08%
Shareholder Yield	-2.08%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a